Kodiak Sciences Inc Common Stock
KODKodiak Sciences Inc (KOD) is a biotechnology company focused on developing ophthalmology and CNS therapies using its proprietary antibody and antibody conjugate platform. Established to address serious retinal diseases, it works on a range of innovative treatments aimed at unmet medical needs in eye health.
Company News
A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers thera...
The Russell 2000 small-cap index reached an intraday record high on Friday, capping a 13-day rally—its best run since 2020. The surge was driven by President Trump's announcement of a two-week military pause against Iran, which lowered oil prices and boosted expectations for Federal Reserve rate cuts. Regional banks, industrials, and biotech st...
Several stocks saw significant gains on Thursday, with Ameresco receiving a bullish upgrade from Jefferies, Lithium Americas experiencing potential government interest, and Kodiak Sciences getting an analyst upgrade.
The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
